Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Healthcare, engg least favoured today
Thu, 23 Apr Closing

The Indian markets ended the day on a weak note, amidst a volatile final hour trading session. The BSE-Sensex closed lower by about 160 points or 0.56% while the NSE-Nifty closed lower by about 31 points or 0.4%. Midcaps ended the day on a firm note (up 0.6%), while smallcaps closed weak with the representative index ending lower by 0.2%. Amongst the sectoral indices pharmaceuticals, engineering and realty stocks were the least preferred, while consumer durables and metal stocks were amongst the key gainers.

At the time of writing, the INR was trading at 63.19 to the US$. Stocks in Europe were largely trading weak.

Indian pharma stocks have ended largely on a weak note, with Indoco remedies and JB Chemicals being the top gainers in the pack, while Natco Pharma and Sun Pharma witnessing the maximum selling pressures. As per a financial daily, Biocon is planning to list its subsidiary Syngene. Biocon holds approx 86% stake in Syngene. The company has filed draft red herring prospectus (DRDP) and expects Syngene to get listed around July 2015. Reportedly, Biocon will be offloading 10% stake of Syngene, since the company needs funds to support is ongoing research and development plans. Biocon has been planning to list Syngene for a while now. The shares of Biocon closed up by approx 1%.

Most of the food & tobacco stocks are trading in the green with Golden Tobacoo and United Spirits being the major gainers. However, Sterling Biotech and VST Industries are trading in the red. VST Industries announced its results for the quarter ended March 2015. The company registered a 16% YoY topline growth for the quarter. But higher input costs led to a 4.3% contraction in operating margin for the quarter. Net profits slumped by 21.6% YoY for the quarter on a 1.3% increase in operating profit and 73.5% fall other income earned. For FY15, the company's sales increased by 6% YoY but net profits were down marginally on account of lower other income. The company has declared a dividend of Rs 70 per share of face value of Rs 10 each for FY15, subject to shareholder's approval. VST Industries closed lower by 3% today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Healthcare, engg least favoured today". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.